Welcome to our dedicated page for Eupraxia Pharmac SEC filings (Ticker: EPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eupraxia Pharmaceuticals Inc. (EPRX) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market and Toronto Stock Exchange. Eupraxia files under the multijurisdictional disclosure system, using Form 40-F for annual reporting and Form 6-K for current reports under the Securities Exchange Act of 1934.
Recent Form 6-K submissions for Eupraxia include press releases, consolidated financial statements, and management’s discussion and analysis for specific periods. For example, filings incorporate interim financial statements and MD&A for quarters ended June 30 and September 30, as well as press releases summarizing clinical data from the RESOLVE trial, financial results, and details of public offerings of common shares. Some 6-Ks also attach material change reports, underwriting agreements, and certifications of interim filings by senior officers.
For investors analyzing EPRX, these filings are key sources of information on clinical development, financial position, and capital markets activity. They describe the status of EP-104GI and EP-104IAR, outline risk factors and forward-looking statements, and explain how proceeds from offerings are intended to support clinical trials, regulatory submissions, manufacturing scale-up, and pipeline expansion. They also discuss operational considerations such as reliance on third-party manufacturers and contract research organizations, and potential impacts of tariffs on clinical supplies.
On Stock Titan, Eupraxia’s filings are updated as new documents are posted to EDGAR, and AI-powered summaries help interpret lengthy exhibits. Users can quickly see which 6-Ks contain financial statements, which include clinical data press releases, and how each filing fits into the broader narrative of EPRX’s development programs and funding strategy.
Eupraxia Pharmaceuticals Inc. submitted a Form 6-K as a foreign private issuer for November 2025. The report furnishes consolidated financial statements and management’s discussion and analysis for the three and nine months ended September 30, 2025, along with a November 4, 2025 press release.
The filing also includes interim certification forms signed by the Chief Executive Officer and Chief Financial Officer, and incorporates the attached financial statements and MD&A by reference into the company’s existing Form F-10 and Form S-8 registration statements.
Amendment No. 1 to a Schedule 13D reports that Joseph S. Freedman increased his beneficial stake in Eupraxia Pharmaceuticals Inc. (EPRX) by purchasing 543,130 common shares in an underwritten public offering at $5.50 per share, for an aggregate purchase price of $2,987,215 paid from his personal funds. The filing shows the Reporting Person now beneficially owns 5,533,215 shares (including common shares, preferred-share equivalents, options and warrants), representing 10.2% of the issuer's diluted common-equivalent share count based on the issuer’s reported outstanding shares.
The amendment discloses a customary 90-day lock-up agreement with the offering underwriters restricting transfers, and option agreements granting certain consultants the ability to purchase 60,000 common shares from shares beneficially owned by the Reporting Person. No other transactions in the prior 60 days were reported.
Eupraxia Pharmaceuticals is offering common shares and other securities under a shelf prospectus for aggregate proceeds up to US$200.0 million. The supplement describes an at-the-market/underwritten offering with per-share pricing shown at US$5.50 and related totals (e.g., US$70,000,001.50 and US$65,100,001.39 depending on options). Proceeds are allocated to clinical development, scale-up and corporate purposes, with explicit estimated line items including US$28.4 million, US$5.0 million, US$7.1 million and US$3.4 million. The company is developing EP-104 family products: EP-104IAR (knee OA) and EP-104GI (EoE), with ongoing Phase 1b/2a and Phase 2/Phase 3 planning and FDA interactions described. The prospectus details securities, dilution mechanics, tax and PFIC considerations for U.S. holders, risks including regulatory, clinical trial, funding and commercialization uncertainties, and potential reliance on partners and CROs.
Eupraxia Pharmaceuticals Inc. is offering securities under a shelf prospectus of up to US$200,000,000 in one or more series, including common shares, preferred shares, debt, warrants, subscription receipts and units. The prospectus supplement discusses two lead product candidates: EP-104IAR (intra-articular injections for knee osteoarthritis; completed a Phase 2 study) and EP-104GI (submucosal injections for eosinophilic esophagitis; open-label Phase 1b/2a RESOLVE trial ongoing). The company received pre-IND/FDA feedback and reached agreement with FDA on late-phase requirements for EP-104IAR and program requirements for EP-104GI. The filing notes material risks: significant additional funding will be required, development and regulatory approval are uncertain, clinical CRO performance and manufacturing/GMP compliance are necessary, potential dilution from existing warrants/options/convertible securities (including 8,905,638 Series 1 Preferred Shares at C$5.00) and loss of foreign private issuer status could increase U.S. compliance costs. The company may seek partners for development and plans to allocate proceeds to clinical development, R&D, manufacturing scale-up and general corporate purposes.